中文 | English




毛斐，副教授，博士生导师

地址：梅陇路130号实验18楼431室

Email：maofei@ecust.edu.cn



个人简介

2014年6月毕业于中山大学药学院药物化学专业，获博士学位，后进入华东理工大学药学院从事博士后研究，合作导师为李剑教授。2016年10月出站后留校工作，从事药物化学教学和科研工作。

瞄准临床重大需求和亟待解决难题，致力于临床未满足重大疾病候选新药研发工作。主要从事基于老药新用策略的药物新靶标发现与候选新药研发工作，涉及妇科肿瘤、金黄色葡萄球菌耐药菌感染、阿尔茨海默病、脑卒中等多个疾病研究领域。迄今已在国内外重要刊物如Adv. Sci., J. Med. Chem., Eur. J. Med. Chem.,Pharmacol. Res.，Cell Death Dis. 等上发表SCI论文70余篇；申请发明专利34项，授权20项（包括国外专利6项）。作为项目负责人，先后主持国家自然科学基金青年基金1项、面上项目2项、上海市自然科学基金面上项目1项、博士后科学基金（面上一等资助）1项、教育部高校基本科研业务费1项；2017年入选上海市“青年科技英才扬帆计划”；2018年入选华东理工大学“青年英才培育计划”A类；作为研究骨干参与国家新药创制重大专项1项，国家重点研发计划课题1项；获教育部自然科学奖一等奖，上海市科技进步奖二等奖；参编《药物结构优化—设计策略和经验规则》论著和国家一流本科课程教材《药物化学》。

主要研究方向

1、抗肿瘤药物新靶标发现、确证与机制研究

2、抗肿瘤药物设计合成与候选新药研发

3、老药新用与老药二次研发

教育经历

2009.9 – 2014.6，中山大学，药学院，药物化学，博士；

2005.8 – 2009.6，沈阳药科大学，制药工程学院，应用化学，学士。

工作经历

2018.9 – 至今，华东理工大学，药学院，副教授；

2016.11 – 2018.8，华东理工大学，药学院，讲师；

2014.7 – 2016.10，华东理工大学，药学院，师资博士后。

招生专业

药学一级学科（博士/硕士/专硕）

欢迎有志于药物化学、药理学及新药研发领域研究的优秀学生加入！

代表性论文(#共同第一作者，*为通讯作者)

  1. Wen Gan#, Xinyu Liu#, Yikang Zhou#, Wei Gu, Xiaohu Liu, Lingyi Song, Jian Li*, Yudong Wang*,  Fei Mao*. Aripiprazole as an inhibitor of EGFR/PI3K/AKT signaling pathway and sensitizer of MPA suppressed progestin-resistant endometrial cancer cells. Arch. Pharm. 2025, 358, e70017.

  2. Lingyi Song#, Huiwen Wu#, Xiao Sun#, Xiaohu Liu#, Xianwu Ling, Wei Ni, Lijuan Li, Beibei Liu, Jinlian Wei, Xiaokang Li, Jian Li*, Yudong Wang*, Fei Mao*. Penfluridol targets septin7 to suppress endometrial cancer by septin7-Orai/IP3R-Ca2+-PIK3CA pathway. iScience 2025, 28, 111640.

  3. Xianwu Ling#, Jiahui Zhang#, Lingyi Song#, Huiwen Wu#, Qi Wang, Xiaohu Liu, Wei Ni, Jian Li*, Yudong Wang*, Fei Mao*. Discovery of novel azaphenothiazine derivatives to suppress endometrial cancer by targeting GRP75 to impair its interaction with IP3R and mitochondrial Ca2+ homeostasis. J. Med. Chem. 2024, 67, 13829−13851.

  4. Qi Wang#, Lijuan Li#, Xiaoyan Gao#, Chunxue Zhang, Chen Xu, Lingyi Song, Jian Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Targeting GRP75 with a Chlorpromazine Derivative Inhibits Endometrial Cancer Progression Through GRP75–IP3R-Ca2+-AMPK Axis. Adv. Sci. 2024, 11, 2304203.

  5. Chunxue Zhang#, Xiaojing Lu#, Ting Ni , Qi Wang, Xiaoyan Gao, Xiao Sun, Jian Li, Fei Mao*, Jin Hou*, Yudong Wang*. Developing patient-derived organoids to identify JX24120 inhibit SAMe synthesis in endometrial cancer by targeting MAT2B. Pharmacol. Res. 2024, 209, 107420.

  6. Lijuan Li#, Xiaohu Liu#, Yunxia Cui, Yang Chen, Huiwen Wu, Jing Wang, Xiaodi Gong, Xiaoyan Gao, Linlin Yang, Jian Li, Xiao Sun*,Fei Mao*, Yudong Wang*. Novel chlorpromazine derivatives as anti-endometrial carcinoma agents with reduced extrapyramidal side effects. Bioorg. Chem. 2022, 127, 106008.

  7. Keting Bao#, Yongyun Li#, Jinlian Wei#, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao*, Renbing Jia*, Jian Li*. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.Cell Death Dis. 2021, 12, 380.

  8. Yunxia Cui, Huiwen Wu, Linlin Yang, Ting Huang, Jian Li, Xiaodi Gong, Lijuan Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Chlorpromazine sensitizes progestin-resistant endometrial cancer cells to MPA by upregulating PRB. Front. Oncol. 2021, 11, 665832.

  9. Linghao Hu#, Hongxuan Feng#,Hongguang Zhang, Songda Yu, Qinyuan Zhao, Wei Wang, Fengxia Bao, Xun Ding, Jiajing Hu, Manjiong Wang, Yixiang Xu, Zengrui Wu, Xiaokang Li, Yun Tang, Fei Mao*, Xiaoyan Chen, Haiyan Zhang*, Jian Li*. Development of Novel N-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents. J. Med. Chem. 2020, 63, 1051-1067.

  10. Yang Chen#, Yunxia Cui#, Xiao Sun#, Huiwen Wu, Manjiao Ou, Yunzhe Tang, Shuaishuai Ni, Xiaokang Li, Jin Zhu, Fei Mao*, Yudong Wang* and Jian Li*. Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. Bioorg. Med. Chem Lett. 2020, 30, 127239.

  11. Wenwen Liu#, Huan Wang#, Xiaokang Li#, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorg. Med. Chem.2018, 26, 3117–3125.

  12. Baoli Li#, Shuaishuai Ni#, Fei Mao#, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J. Med. Chem. 2018, 61, 224–250.

  13. Fei Mao#, Huan Wang#, Wei Ni#, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2018, 9, 328–345.

  14. Hanwen Wei#, Fei Mao#, Shuaishuai Ni#, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. Eur. J. Med. Chem. 2018, 145, 235–251.

  15. Yi-xiang Xu#, Huan Wang#, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*, Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2018, 143, 33–47.

  16. Xiaokang Li#, Huan Wang#, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. ACS Chem. Neurosci. 2017, 8, 2708–2721.

  17. Yanli Lu#, Fei Mao#, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs). J. Med. Chem. 2017, 60, 5099–5119.

  18. Xiaokang Li#, Huan Wang#, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, and Fei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 8326−8344.

  19. Dengwei Wu#, Fei Mao#, Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus. Acta Pharmacol. Sin. 2015, 36, 1126-1136.

  20. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. J. Enzym. Inhib. Med. Chem.2015,30, 995-1001.